drug
Aduhelm
Discontinuedupdated 3mo agoby $BIIB BIOGEN INC.
community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying Aduhelm
- EP1Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy
- phase3A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
- phase3A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
- phase3A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)
News(1)
- Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the storeWith so many unknowns, Biogen is carefully eyeing its next-gen Alzheimer’s treatment diranersen as a high-risk, high-reward project with the potential for a major payout around 2030.biospace · 18d ago
Data sources
last refreshed 6m ago
Found something off?
comments(0)
5-min edit window · permanent after that